Description
Michael S. Lloyd, MD, FHRS of Emory University discusses Catheter Ablation of Atrial Fibrillation in Adult Congenital Heart Disease: Procedural Characteristics and Outcomes with Natasja M. S. De Groot, MD, PhD, of Erasmus University Medical Center, and Jeremy P. Moore, MD, MS, FHRS, CCDS, CEPS-P, of UCLA Medical Center.
Learning Objectives
- Describe the differences between catheter ablation of AF in a patient with adult congenital heart disease versus those without.
- List the limitations of this study's methodology.
- Explain how the findings of this study could affect clinical practice.
Article Authors and Podcast Contributors
Article Authors
Tiffany Y. Hu, MD, Chaitra Janga, MBBS, Mustapha Amin, MD, Nicholas Y. Tan, MD, MS, David O. Hodge, MS, Ramila A. Mehta, MS, Christopher J. McLeod, MBBCh, PhD, Anca Chiriac, MD, PhD, William R. Miranda, MD, Heidi M. Connolly, MD, Samuel J. Asirvatham, MD, Abhishek J. Deshmukh, MBBS, Alexander C. Egbe, MBBS, MPCH, Malini Madhavan, MBBS
Podcast Contributors
Michael S. Lloyd, MD, FHRS, of Emory University
Natasja M. S. De Groot, MD, PhD, of Erasmus University Medical Center
Jeremy P. Moore, MD, MS, FHRS, CCDS, CEPS-P, of UCLA Medical Center
Disclosure Policy
ACE Disclosure Policy
The Heart Rhythm Society is committed to the provision of Accredited Continuing Education (formerly known as Continuing Medical Education (CME)) that is balanced, objective, and evidence based. HRS adheres to the Standards for Integrity and Independence in Accredited Continuing Education of the Accreditation Council for Continuing Medical Education (ACCME) which require that those individuals in a position to control the content of an educational activity (including, but not limited to, planners, faculty, authors, committee members, content reviewers, editors, and staff) disclose all financial relationships with an ACCME-defined ineligible company* within the 24 months prior to the disclosure.
Any individual who refuses to disclose financial relationships is disqualified from participating in HRS ACE-certified activities. Owners and employees of ACCME-defined ineligible companies may have no role in the planning or implementation of ACE activities without a special written exemption from the HRS Chief Learning Officer that will be granted only in specific circumstances that meet ACCME requirements.
ACCME Definition:
*An ineligible company is one whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
Examples of such organizations include:
- Advertising, marketing, or communication firms whose clients are ineligible companies
- Bio-medical startups that have begun a governmental regulatory approval process
- Compounding pharmacies that manufacture proprietary compounds
- Device manufacturers or distributors
- Diagnostic labs that sell proprietary products
- Growers, distributors, manufacturers or sellers of medical foods and dietary supplements
- Manufacturers of health-related wearable products
- Pharmaceutical companies or distributors
- Pharmacy benefit managers
- Reagent manufacturers or sellers
All relevant financial relationships have been mitigated.Host Disclosure(s):
M. Lloyd: Honoraria/Speaking/Consulting Fee: Medtronic, Baylis Medical Company, Boston Scientific
Contributor Disclosure(s):
N. De Groot: Honoraria/Speaking/Consulting Fee: Biosense Webster
J. Moore: No relevant financial relationships with ineligible companies to disclose.
Staff Disclosure(s) (note: HRS staff are NOT in control of educational content. Disclosures are provided solely for full transparency to the learner):
J. Glenn: No relevant financial relationships with ineligible companies to disclose.
S. Sailor: No relevant financial relationships with ineligible companies to disclose.